“The success of a medtech start-up is defined by the global impact of its products. For us, our solutions are being used by pharmaceuticals [in US clinical trials],” says Gideon Ho, CEO of HistoIndex.
A Worldwide Effort to Defeat Nonalcoholic Steatohepatitis (NASH) The silent disease known as NASH is on the rise worldwide. Therefore, stronger public awareness is needed in detecting NASH and fibrosis early in order to facilitate timely and quality medical intervention. With the liver biopsy as the current gold standard for NASH diagnosis, HistoIndex can …
A Worldwide Effort to Defeat Nonalcoholic Steatohepatitis (NASH) Read More »
Singapore HQ
Teletech Park
20 Science Park Road, #01-26/27
Singapore 117674
UK Branch
Queen Elizabeth University Hospital,
Imaging Centre of Excellence, L3-18, Langlands Drive, Glasgow G51 4LB,
United Kingdom
China Subsidiary Office
Room 1001, Building 10
No. 188 Binkang Road, Hangzhou
Zhejiang 310051, China
©2024 Histoindex Pte Ltd. All Rights Reserved. All logos and trademarks are the property of HistoIndex or their respective owners.